J Chen, Q N Ping, J X Guo, X Z Chu, M M Song
Index: Drug Dev. Ind. Pharm. 32(6) , 719-26, (2006)
Full Text: HTML
9-Nitrocamptothecin (9-NC), a newly developed camptothecin derivative, had poor solubility in any pharmaceutically acceptable solvents. One way of improving the solubility is to formulate the drug into liposomes. However, 9-NC has low affinity to lipid membranes resulting in a very low drug-to-liposome entrapment. We developed a novel liposome-based 9-NC formulation which was composed of soybean phosphatidylcholine (SPC), hydrogenated soybean phosphatidylcholine (HSPC), and cholesterol. Compared with conventional liposomes composed of only SPC and cholesterol, 9-NC/lipid molar ratio increased from 1:72 to 1:18 while incorporation efficiency was still maintained about 80%. In addition, after 9-NC was encapsulated into novel liposomes, pharmacokinetic results revealed an increase in area under the plasma concentration-time curve (AUC) and a decrease in distribution volume of 9-NC following intravenous administration to rats. Increased stability in plasma may account for the improved pharmacokinetic behavior of the novel liposomes. Effect of HSPC/SPC molar ratio on characterization of the novel liposomes was also investigated. Except for drug/lipid molar ratio and encapsulation efficiency, HSPC/SPC molar ratio had only a little effect on other properties of novel liposomes. In conclusion, the study suggests that the novel liposomes can act as promising carriers for hydrophobic substances such as 9-NC.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
rubitecan
CAS:91421-42-0 |
C20H15N3O6 |
Effect of injection routes on pharmacokinetics and lactone/c...
2007-08-01 [Int. J. Pharm. 340(1-2) , 29-33, (2007)] |
Sequential oral 9-nitrocamptothecin and etoposide: a pharmac...
2006-08-01 [Mol. Cancer Ther. 5(8) , 2130-7, (2006)] |
9-nitrocamptothecin polymeric nanoparticles: cytotoxicity an...
2008-09-01 [Anticancer Drugs 19(8) , 805-11, (2008)] |
Anticancer activity of new haloalkyl camptothecin esters aga...
2012-09-01 [Anticancer Agents Med. Chem. 12(7) , 818-28, (2012)] |
Key role of topoisomerase I inhibitors in the treatment of r...
2008-05-01 [Expert Rev. Anticancer Ther. 8(5) , 819-31, (2008)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved